Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results - ...

The MOU marks a significant step in strengthening the Kingdom’s healthcare sector and pharmaceutical manufacturing ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The global capability centre of Novo Nordisk in India is now closely engaged with the entire value chain of this global ...

Shares in Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Novo Holdings and the Export and Investment Fund of Denmark (EIFO) have jointly invested €48 million in HealthCap IX, a Swedish life ...

Indian diabetic population on Human Mixtard concerned on changes in insulin therapy: Nandita Vijayasimha, Bengaluru Thursday, April 24, 2025, 08:00 Hrs [IST] India’s diabetic po ...

Novo Nordisk clarifies Human Mixtard penfill to be replaced with injectables: Our Bureau, Bengaluru Wednesday, April 23, 2025, 13:30 Hrs [IST] Denmark-based global pharma major, N ...

Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today ...